Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential

As previously reported, Brookline analyst Kemp Dolliver initiated coverage of Y-mAbs Therapeutics (YMAB) with a Buy rating and $17 price target. Danyelza, which has accelerated approval from the FDA for the treatment, in combination with GM-CSF, of pediatric patients one year of age and older and adult patients with high risk neuroblastoma in the bone or bone marrow, has made “steady gains” against United Therapeutics’ (UTHR) Unituxin since its U.S. launch, the analyst tells investors. The firm expects Danyelza’s U.S. revenue growth to recover in 2025 and 2026 as average cycles/patient recover and longer term expects annual price increases of 5%, the analyst noted.